Compile Data Set for Download or QSAR
Found 185 with Last Name = 'pulz' and Initial = 'ra'
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239101(US10195181, Example 2.2 | US9403810, 2.2)copy SMILEScopy InChI
Affinity DataIC50: 0.900nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239101(US10195181, Example 2.2 | US9403810, 2.2)copy SMILEScopy InChI
Affinity DataIC50: 0.900nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200756(US9233111, 1)copy SMILEScopy InChI
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200783(US9233111, 17)copy SMILEScopy InChI
Affinity DataIC50: 1nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239132(US9403810, 22c)copy SMILEScopy InChI
Affinity DataIC50: 1.40nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239117(US10195181, Example 22c | US9403810, 22)copy SMILEScopy InChI
Affinity DataIC50: 1.40nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239094(US10195181, Example 1.3 | US9403810, 1.3)copy SMILEScopy InChI
Affinity DataIC50: 1.80nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239094(US10195181, Example 1.3 | US9403810, 1.3)copy SMILEScopy InChI
Affinity DataIC50: 1.80nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200888(US9233111, 63)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200778(US9233111, 16)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200887(US9233111, 62)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200768(US9233111, 6)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200766(US9233111, 4)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200802(US9233111, 25)copy SMILES
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200860(US9233111, 47)copy SMILEScopy InChI
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200881(US9233111, 56)copy SMILES
Affinity DataIC50: 2nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239092(US10195181, Example 1.1 | US9403810, 1.1)copy SMILEScopy InChI
Affinity DataIC50: 2.10nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239092(US10195181, Example 1.1 | US9403810, 1.1)copy SMILEScopy InChI
Affinity DataIC50: 2.10nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239099(US10195181, Example 2 | US9403810, 2)copy SMILEScopy InChI
Affinity DataIC50: 2.5nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239099(US10195181, Example 2 | US9403810, 2)copy SMILEScopy InChI
Affinity DataIC50: 2.5nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239091(US10195181, Example 1 | US9403810, 1)copy SMILEScopy InChI
Affinity DataIC50: 2.80nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239091(US10195181, Example 1 | US9403810, 1)copy SMILEScopy InChI
Affinity DataIC50: 2.80nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200770(US9233111, 8)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200767(US9233111, 5)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200769(US9233111, 7)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200884(US9233111, 59)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200817(US9233111, 31)copy SMILEScopy InChI
Affinity DataIC50: 3nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239095(US10195181, Example 1.4 | US9403810, 1.4)copy SMILEScopy InChI
Affinity DataIC50: 3.20nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239095(US10195181, Example 1.4 | US9403810, 1.4)copy SMILEScopy InChI
Affinity DataIC50: 3.20nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200878(US9233111, 55)copy SMILES
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200775(US9233111, 13)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200774(US9233111, 12)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200764(US9233111, 2)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200825(US9233111, 36)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200819(US9233111, 33)copy SMILEScopy InChI
Affinity DataIC50: 4nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200773(US9233111, 11)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200771(US9233111, 9)copy SMILEScopy InChI
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200765(US9233111, 3)copy SMILES
Affinity DataIC50: 5nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239105(US10195181, Example 6 | US9403810, 6)copy SMILEScopy InChI
Affinity DataIC50: 5.70nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239105(US10195181, Example 6 | US9403810, 6)copy SMILEScopy InChI
Affinity DataIC50: 5.70nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239096(US10195181, Example 1.5 | US9403810, 1.5)copy SMILEScopy InChI
Affinity DataIC50: 6nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetE3 ubiquitin-protein ligase SMURF1 [420-757](Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239102(US10195181, Example 3 | US9403810, 3)copy SMILEScopy InChI
Affinity DataIC50: 6nMT: 2°CAssay Description:For the biochemical assay panel, 50 nl of the test compounds, reference compounds and buffer/DMSO control are transferred to the respective wells of ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q22V2F1FUS Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239096(US10195181, Example 1.5 | US9403810, 1.5)copy SMILEScopy InChI
Affinity DataIC50: 6nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetE3 ubiquitin-protein ligase SMURF1(Homo sapiens (Human))
Novartis AG

US Patent
LigandPNGBDBM239102(US10195181, Example 3 | US9403810, 3)copy SMILEScopy InChI
Affinity DataIC50: 6nMAssay Description:To determine the HECT E3 ligase selectivity of the compounds, a panel of biochemical HECT E3 ligase autoubiquitinylation assays was employed (Smurf-1...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q28054Q2US Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200784(US9233111, 18)copy SMILES
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200786(US9233111, 20)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200789(US9233111, 21)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200816(US9233111, 30)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200886(US9233111, 61)copy SMILEScopy InChI
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
TargetTyrosine-protein kinase BTK(Homo sapiens (Human))
NOVARTIS AG

US Patent
LigandPNGBDBM200818(US9233111, 32)copy SMILEScopy InChI
Affinity DataIC50: 7nMpH: 7.5 T: 2°CAssay Description:The inhibitory activity of the present compounds against Btk was assessed in a biochemical enzyme assay. Assay plates in 384 well format were prepare...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
BindingDB Entry DOI: 10.7270/Q2ZS2V9CUS Patent
Displayed 1 to 50 (of 185 total ) | Next | Last >>
Jump to: